Exactly. And you can bet shortie knows exactly what the rescheduling means. "After industry and thought leader input we have reassessed our draft guidance". I can see it now; just wish we wouldn't have to wait a year. Time will tell; I can only imagine the horsetrading behind the new FDA appointment.
Candy--of course it 'works'--whatever that means. If true, it will be money you have to come up with or utilize a LOC for. Of course it won't harm the big guys with deep credit lines. But it just might affect some others. In any event, a sure sign of a growing company.
Co. has cash on hand and it's a more effective way, in my view, than a buyback, to aggravate the boys from Boca and others that are in the game. Even a $0.10 dividend would hurt, particularly if they could project that for the future and not just a one time 'special' dividend. Perhaps that's why the stock has performed better relative to IBB in general? Earnings will be a blow out. Weather has been fab and sales won't suffer from cancelled procedures.
Stem--my view is zero chance that's a cover. Just MM's rearranging inventory and processing trades later in the day. My thesis has been, is, and will be that shorts never ever cover until they must. They don't short into a spike high, but may cover some into a low. Their process is exactly the opposite of a long trader. No chance for a cover until they know they are beaten; that day will come but is not here. Good luck to the longs. What a well run company!
Doc I believe you're correct about the second half. Nice solid release and you can bet management will beat. Weather in Q1 will not have the impact it did in 2015. What a well run company with a well executed business plan.
The KBIO squeeze is inspiring but short of a private company acquiring MDXG probably can't happen given the large float. It is an awesome spectacle to see the naked short squeezed again and again as the borrow is pulled from beneath their feet. Trading in the $40's this afternoon. How are those Ferragamo's doing boys???
Maybe but I think his tilt would be toward not splitting hairs on the 'material' part given the SEC witch hunt in the past. Either way we can both completely agree he has enough stock!!!
how--if a company officer is in possession of material information that is not in the public domain they can not buy their stock. How nutty would it be otherwise: let's say a big company is buying a little company. Can the big co CEO buy his own stock? Can he buy the little stock (poised to pop if public?)? Same answer for both: He can't buy either.
This was out before the close and is already digested so there will be no pop tomorrow. Unfortunately this something that will create 'uncertainty' for the stock when no uncertainty is warranted. There is no gray here, just government gobbley#$%$ that creates confusion. Thousands of people monthly would go blind if those grafts were ever pulled [ trust me on that ;) ]. Amputations too. FDA has no interest in that. As I said before, the operative word is 'should' and that's what the company has done and will stick too. This is indeed a fire sale and revenues, guidance, etc will prove that. HOWEVER, that being said, I would love a BLA to allow explicit labelling.
Finally a well composed, concise non defensive press release issued last evening. As I mentioned earlier, the operative word in the guidance is 'should'. It will take a while for the market to grasp this but today's release will help that process. Nothing has changed.
google 'fda recently issued guidance documents' it will be the most recent document. The key word is 'should' I don't think this is relevant to its core business but certainly could impact the injectable in my opinion.